LYMPHOMA NON-HODGKIN
Clinical trials for LYMPHOMA NON-HODGKIN explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA NON-HODGKIN trials appear
Sign up with your email to follow new studies for LYMPHOMA NON-HODGKIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lymphoma drug trial halted early after safety check
Disease control TerminatedThis early-stage study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas that had not responded to other treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Matched conditions: LYMPHOMA NON-HODGKIN
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Experimental combo for tough lymphoma shows early promise
Disease control TerminatedThis early-stage trial tested a combination of two drugs, tazemetostat and venetoclax, in people with Non-Hodgkin lymphoma that had returned or stopped responding to standard treatments. The main goals were to find the safest dose of venetoclax to use with tazemetostat and to see…
Matched conditions: LYMPHOMA NON-HODGKIN
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 13, 2026 16:02 UTC